Close
0
You have no items in your order cart.
Search
Filters

Purevax Rcp Felv - 1ml x10

Active immunisation of cats aged 8 weeks and older against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs and viral excretion; against feline panleucopenia to prevent mortality and reduce clinical signs; and against feline leukaemia to prevent persistent viraemia and reduce clinical signs of the disease. Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. The duration of immunity is 1 year after the last (re)vaccination for rhinotracheitis, calicivirus and feline leukaemia components, and 3 years for panleucopenia component. Dosage and administration 1 ml by subcutaneous injection after reconstitution of the freeze-dried pellet with the solvent, according to the following schedule: Primary vaccination: First injection: from 8 weeks of age, Second injection: 3 to 4 weeks later. Revaccination: For all components one year after the primary vaccination course, then every year for the rhinotracheitis, calicivirosis and feline leukaemia components, and every three years for the panleucopenia component. Where high levels of maternal antibodies against R, C or P components are expected to be present (e.g. in kittens of 9 - 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

This is a restricted product.
Please visit your Favourites List in My Account to purchase this item.

Availability: Out of Stock - on backorder and will be dispatched once in stock.
SKU: 104161
Customers who bought this item also bought

Dispensing Envelope

144684
For dispensing wrom treatments to patients.

Nobi-Vac Kc. - 1ml x5

121660
A live vaccine against canine infectious tracheobronchitis caused by B. bronchiseptica and parainfluenza virus in dogs. Infectious tracheobronchitis is a highly contagious, multi-factorial disease of the dog’s respiratory tract. Bordetella bronchiseptica and canine parainfluenza are the most common bacterial and viral agents associated with the disease. Environmental factors such as stress, ventilation and climate may also contribute. Nobivac KC is a low volume dose (0.4ml), easy to administer, intranasal vaccine which acts against both the key causative agents of infectious tracheobronchitis and provides protection within 72 hours and lasts for at least 12 months. It can be used in puppies as young as three weeks and in pregnant bitches.

Eurican Dhppi - 1ml x10

124090
A combined live freeze-dried vaccine against canine distemper, infectious canine hepatitis, canine parvovirus and canine parainfluenza virus type 2. Each 1-ml dose of vaccine contains attenuated canine distemper virus, at least 104.0 CCID50, attenuated canine adenovirus (CAV2), at least 102.5 CCID50, attenuated canine parvovirus, at least 104.9 CCID50, attenuated canine parainfluenza type 2 virus, at least 104.7 CCID50 Uses Dogs and puppies from 8 weeks of age: Active immunization against distemper to reduce mortality and clinical signs; against infectious canine hepatitis to prevent clinical signs; against parvovirus to prevent clinical signs and reduce mortality and viral excretion; and against parainfluenza type 2 infections to reduce clinical signs and viral excretion. Onset of immunity: 2 weeks after completion of the primary vaccination course. Duration of immunity: 1 year. Dosage and administration Reconstitute the vaccine with Eurican L using a clean sterile syringe. Use the vaccine immediately after reconstitution of the freeze-dried pellet. Apply usual aseptic procedures. Use sterile and/or disinfectant-free equipment for injection purposes. Administer by subcutaneous injection. The following vaccination schedule is recommended: Primary vaccination: 1st injection: from 8th week of age. 2nd injection: 3 to 5 weeks later, from 12th week of age. Revaccination: Booster injections should be given annually thereafter.

Eurican L Multi - 1ml x10

141334
Indications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not establishedIndications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not established